Icosabutate

Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis[1]. Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia [2].

Product Specifications

CAS Number

[1253909-57-7]

UNSPSC

12352211

Hazard Statement

H315-H319-H335-H400-H410

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/icosabutate.html

Purity

97.28

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCC(OCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)C(O)=O

Molecular Formula

C24H38O3

Molecular Weight

374.56

Precautions

P261-P264-P271-P273-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P391-P403+P233-P405-P501

References & Citations

[1]van den Hoek AM, et al. Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice.Hepatol Commun. 2019 Dec 24;4 (2) :193-207.|[2]Kastelein JJ, et al. Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.Cardiology. 2016;135 (1) :3-12.